Drug General Information |
Drug ID |
D06YYY
|
Former ID |
DIB001639
|
Drug Name |
KAR-1880
|
Synonyms |
Anti-inflammatory OS-HDI; OS-HDI-2; HDAC 2 inhibitors (topical, dermatitis/psoriasis), Karus
|
Indication |
Dermatitis [ICD9: 692.9; ICD10:L20-L30]
|
Investigative |
[1]
|
Company |
Karus Therapeutics Ltd
|
Target and Pathway |
Target(s) |
Histone deacetylase 2 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Cell cycle
|
Notch signaling pathway
|
Thyroid hormone signaling pathway
|
Huntington's disease
|
Alcoholism
|
Epstein-Barr virus infection
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Viral carcinogenesis
|
Chronic myeloid leukemia
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Wnt signaling pathway
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Signaling events mediated by HDAC Class I
|
Regulation of Telomerase
|
Glucocorticoid receptor regulatory network
|
Direct p53 effectors
|
Hedgehog signaling events mediated by Gli proteins
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
Reactome
|
p75NTR negatively regulates cell cycle via SC1
|
NOTCH1 Intracellular Domain Regulates Transcription
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
HDACs deacetylate histones
|
NoRC negatively regulates rRNA expression
|
RNA Polymerase I Transcription Initiation
|
Factors involved in megakaryocyte development and platelet production
|
WikiPathways
|
Notch Signaling Pathway
|
Notch Signaling Pathway
|
Neural Crest Differentiation
|
Signalling by NGF
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
Factors involved in megakaryocyte development and platelet production
|
Cell Cycle
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2616). |